Read the latest press releases for 4D pharma plc.

Click on a news title to read full details. For Regulatory News Service (RNS) announcements please click here.

Clinical
4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021
2 Aug 2021, 07:00
4D pharma announces two poster presentations at the European Society for Medical Oncology (ESMO)…
Careers
4D pharma Announces $30 Million Credit Facility with Oxford Finance
29 Jul 2021, 07:00
4D pharma announces the closing of a senior secured credit facility for up to $30m with Oxford…
Careers
4D pharma Announces Passing of Chief Financial Officer John Beck
26 Jul 2021, 13:00
4D pharma announces with great sadness the passing of John Beck, Chief Financial Officer of 4D…
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T
6 Jul 2021, 07:00
4D pharma (AIM: DDDD, NASDAQ: LBPS) announces the publication of pre-clinical research relating to…
4D pharma to Participate in Ladenburg Thalmann Healthcare Conference
29 Jun 2021, 07:00
4D pharma (AIM: DDDD, NASDAQ: LBPS) management will present a corporate overview followed by a…
4D pharma to Present at the Microbiome Movement Drug Development Summit
22 Jun 2021, 07:00
Christophe Carite, Director CMC & Development, 4D pharma plc (NASDAQ: LBPS, AIM: DDDD), will deliver…
4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update
4 Jun 2021, 07:00
4D pharma completes target enrollment of 30 patients for Part A of its Phase I/II clinical trial of…
4D pharma Presents Additional Positive Results of Phase II Study of Blautix® for the Treatment of Irritable Bowel Syndrome
24 May 2021, 07:00
New data demonstrating clinical activity of Live Biotherapeutic Blautix in both IBS-C and IBS-D was…
4D pharma to Present Additional Data from Phase II Study of Blautix for the Treatment of Irritable Bowel Syndrome at Digestive Disease Week (DDW) 2021
17 May 2021, 07:00
4D pharma to Present Additional Data from its completed Phase II Study of Blautix for the Treatment…
4D pharma collaborates with Parkinson’s UK to establish Patient Advisory Board
19 Apr 2021, 07:00
4D pharma announces a collaboration with Parkinson’s UK, a non-profit organization focused on…
4D pharma to Participate in Jefferies Microbiome-Based Therapeutics Summit
15 Apr 2021, 07:00
4D pharma CEO, Duncan Peyton, and CSO, Alex Stevenson, will participate in a fireside chat at the…
4D pharma Announces Instructions for Converting AIM Listed Ordinary Shares into Nasdaq Listed ADSs
7 Apr 2021, 07:00
This announcement is intended to guide holders of Ordinary Shares, which are admitted to trading on…
Final Results for the year ended 31 December 2020
1 Apr 2021, 07:00
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live…
Completion of Merger with Longevity Acquisition Corporation and admission of American Depositary Shares to trading on NASDAQ
22 Mar 2021, 07:00
4D pharma's business combination with Longevity Acquisition Corporation has now become effective,…
4D pharma and Longevity receive shareholder approval to complete business combination
18 Mar 2021, 13:30
4D pharma and Longevity Acquisition Corporation receive shareholder approval to complete business…

BACK TO TOP